NEW YORK--(BUSINESS WIRE)--Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the ...

Synchron’s foundational technology, a motor neuroprosthesis, or motor BCI, is implanted via the jugular vein using neurointerventional techniques commonly used to treat stroke, and does not require ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Synchron has cemented its position as the frontrunner in brain computer interface (BCI) clinical trials, after the company reported positive 12-month safety and efficacy data for its Stentrode device.

Even though brain-computer interfaces (BCIs) are still an emerging part of neurotechnology, Neuralink, Elon Musk's BCI startup, has dominated headlines about the space. But rival company Synchron is ...